ArticleRSC advances2025
Analysis of tear fluid protein fractions using surface-enhanced Raman spectroscopy (SERS), followed by a high-performance liquid chromatography-light emitting diode-induced fluorescence (HPLC-LED-IF) method.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigates the application of surface-enhanced Raman spectroscopy (SERS) in conjunction with high-performance liquid chromatography-light-emitting diode-induced fluorescence (HPLC-LED-IF) for analyzing tear proteins in the diagnosis of ophthalmological conditions. SERS is a highly sensitive technique capable of detecting low-concentration biomolecules in body fluids, enabling the monitoring of protein composition, presence, and relative variations associated with different health conditions. In this study, SERS substrates were fabricated by immobilizing gold nanostars on APTES-functionalized surfaces, leveraging the well-known electric field enhancement at sharp plasmonic edges. Tear protein fractions (PF1 and PF2) obtained from the HPLC system were drop-coated onto these substrates for SERS measurements. Tear fluid samples from control (C), moderate dry-eye (MDE), and primary open-angle glaucoma (POAG) subjects were studied, and the recorded SERS spectra revealed distinct Raman spectral patterns for each disease category. Multivariate analysis using principal component analysis (PCA) for PF1 and PF2 from the control and disease groups explained approximately 88% of the cumulative variance, indicating a clear separation between the groups. Further, classification using
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.